Sun Pharmaceutical Industries Ltd.,
SUN HOUSE, CTS No. 201 B/1,
Western Express HI Highway, Goregaon(E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com

16 December 2022

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sirs,

Sub: Update on Halol facility

This is in continuation to our communications dated May 10, 2022, August 13, 2022 and December 08, 2022 regarding the USFDA inspection at the Company's Halol (Gujarat, India) facility from April 26 to May 9, 2022.

We now wish to inform you that the Company has received Warning Letter from USFDA for the Halol facility. The Warning Letter summarizes violations with respect to Current Good Manufacturing Practice (cGMP) regulations. USFDA shall make public the contents of the Warning Letter in due course.

As per our communication dated December 08, 2022, the Halol facility was placed under Import Alert by USFDA.

This is for your information and dissemination.

Thanking you,

Yours faithfully,
For Sun Pharmaceutical Industries Limited

ANOOP ANJANIKUMAR DESHPANDE
Digitally signed by ANOOP ANJANIKUMAR DESHPANDE
Date: 2022.12.16 19:15:16 +05'30'

Anoop Deshpande
Company Secretary & Compliance Officer